Ziopharm Oncology Inc.'s Phase III trial with the alkylating agent palifosfamide for first-line, metastatic soft tissue sarcoma failed to meet the primary endpoint of progression-free survival (PFS), but the company – shifting its efforts to synthetic biology programs partnered with Intrexon Corp. – will continue to follow patients' overall survival (OS) rates.